These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34775359)

  • 21. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
    Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
    Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New Insights into the Therapeutic Applications of CRISPR/Cas9 Genome Editing in Breast Cancer.
    Ahmed M; Daoud GH; Mohamed A; Harati R
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34066014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
    Tao Y; Yi K; Hu H; Shao D; Li M
    J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges.
    Yi L; Li J
    Biochim Biophys Acta; 2016 Dec; 1866(2):197-207. PubMed ID: 27641687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
    Verma R; Sahu R; Singh DD; Egbo TE
    Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms.
    Dong Z; Qin Q; Hu Z; Chen P; Huang L; Zhang X; Tian T; Lu C; Pan M
    Virol Sin; 2019 Aug; 34(4):444-453. PubMed ID: 31218589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome editing and cancer: How far has research moved forward on CRISPR/Cas9?
    Mitra S; Sarker J; Mojumder A; Shibbir TB; Das R; Emran TB; Tallei TE; Nainu F; Alshahrani AM; Chidambaram K; Simal-Gandara J
    Biomed Pharmacother; 2022 Jun; 150():113011. PubMed ID: 35483191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
    Chen M; Xu J; Zhou Y; Zhang S; Zhu D
    Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR-Cas9 therapies in experimental mouse models of cancer.
    Estêvão D; Rios Costa N; da Costa RG; Medeiros R
    Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR-Cas9 in cancer therapeutics.
    Randhawa S
    Prog Mol Biol Transl Sci; 2021; 181():129-163. PubMed ID: 34127191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
    Jacinto FV; Link W; Ferreira BI
    J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing.
    Wang F; Wang L; Zou X; Duan S; Li Z; Deng Z; Luo J; Lee SY; Chen S
    Biotechnol Adv; 2019; 37(5):708-729. PubMed ID: 30926472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis.
    Hariprabu KNG; Sathya M; Vimalraj S
    Int J Biol Macromol; 2021 Dec; 192():913-930. PubMed ID: 34655593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: A novel paradigm for precision oncology.
    Mahato RK; Bhattacharya S; Khullar N; Sidhu IS; Reddy PH; Bhatti GK; Bhatti JS
    J Biotechnol; 2024 Jan; 379():98-119. PubMed ID: 38065367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in CRISPR/Cas9 Delivery Strategies.
    Yip BH
    Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.